ADMA Biologics (ADMA) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $107.2 million, up 78% year-over-year, driven by ASCENIV and other IG product sales.

• GAAP net income was $32.1 million, reversing a prior year loss, and Adjusted EBITDA rose nearly 600% to $44.5 million.

• Gross margin improved to 53.6%, aided by a $12.6 million Medicaid rebate accrual adjustment.

• ASCENIV now contributes over 50% of total revenue, with supply expansion and market penetration under 3%.

• Management raised 2024 and 2025 guidance for revenue, Adjusted EBITDA, and net income, reflecting strong business momentum.

Financial highlights

• Q2 2024 revenue: $107.2 million, up from $60.1 million in Q2 2023 (+78%).

• Q2 2024 gross profit: $57.5 million (53.6% margin), up from $16.7 million (27.8% margin) year-over-year.

• Q2 2024 net income: $32.1 million vs. net loss of $6.4 million in Q2 2023.

• Adjusted EBITDA: $44.5 million, up from $6.4 million in Q2 2023.

• Q2 results benefited from a one-time $12.6 million accrual reversal related to Medicaid rebates.

Outlook and guidance

• 2024 revenue expected to exceed $400 million; 2025 revenue expected at $445 million.

• Adjusted EBITDA guidance: over $150 million for 2024 and $200 million for 2025.

• Net income guidance: over $105 million for 2024 and $155 million for 2025.

• Yield enhancement initiatives and ASCENIV production scale could further boost peak financial targets.

• Cash, equivalents, and receivables expected to fund operations through at least Q3 2025.